IN2015DN01728A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN01728A IN2015DN01728A IN1728DEN2015A IN2015DN01728A IN 2015DN01728 A IN2015DN01728 A IN 2015DN01728A IN 1728DEN2015 A IN1728DEN2015 A IN 1728DEN2015A IN 2015DN01728 A IN2015DN01728 A IN 2015DN01728A
- Authority
- IN
- India
- Prior art keywords
- composition
- nanocapsules
- minoxidil
- finasteride
- alopecia
- Prior art date
Links
- 239000002088 nanocapsule Substances 0.000 abstract 3
- 201000004384 Alopecia Diseases 0.000 abstract 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 abstract 2
- 231100000360 alopecia Toxicity 0.000 abstract 2
- 229960004039 finasteride Drugs 0.000 abstract 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 abstract 2
- 229960003632 minoxidil Drugs 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000000699 topical effect Effects 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to a pharmaceutical composition of topical application for the treatment of alopecia the composition comprising polymeric nanoparticles preferably nanocapsules containing two active principles finasteride and minoxidil and pharmaceutically acceptable additives and carriers. The invention further includes a method for preparing polymeric finasteride and minoxidil nanoparticles preferably nanocapsules suitable for a composition of topical application for the treatment of alopecia as well as the use of said nanocapsules for preparing a pharmaceutical composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR102012022036-9A BR102012022036B1 (en) | 2012-08-31 | 2012-08-31 | FINASTERIDE AND MINOXIDIL POLYMERIC NANOParticle, PROCESS OF PREPARATION, WATER-CONTAINING SUSPENSION, PHARMACEUTICAL COMPOSITION, AND ITS USE |
| PCT/BR2013/000335 WO2014032152A1 (en) | 2012-08-31 | 2013-08-30 | Polymeric finasteride and minoxidil nanoparticles, method for preparing same, aqueous suspension containing same, pharmaceutical composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN01728A true IN2015DN01728A (en) | 2015-05-29 |
Family
ID=50182296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1728DEN2015 IN2015DN01728A (en) | 2012-08-31 | 2013-08-30 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9687554B2 (en) |
| EP (1) | EP2891486B1 (en) |
| JP (1) | JP6352265B2 (en) |
| KR (1) | KR102118582B1 (en) |
| CN (1) | CN104755075B (en) |
| AR (1) | AR092403A1 (en) |
| AU (1) | AU2013308356B2 (en) |
| BR (1) | BR102012022036B1 (en) |
| CA (1) | CA2883998C (en) |
| CL (1) | CL2015000501A1 (en) |
| CO (1) | CO7310520A2 (en) |
| DK (1) | DK2891486T3 (en) |
| ES (1) | ES2683418T3 (en) |
| IN (1) | IN2015DN01728A (en) |
| MX (1) | MX363961B (en) |
| MY (1) | MY174692A (en) |
| PE (2) | PE20150732A1 (en) |
| SA (1) | SA515360084B1 (en) |
| TR (1) | TR201810389T4 (en) |
| UA (1) | UA113774C2 (en) |
| UY (1) | UY35002A (en) |
| WO (1) | WO2014032152A1 (en) |
| ZA (1) | ZA201501255B (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150174254A1 (en) * | 2013-12-23 | 2015-06-25 | Mcneil-Ppc, Inc. | Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent |
| US9675537B2 (en) * | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
| CN104887685A (en) * | 2015-05-05 | 2015-09-09 | 谢秉权 | Compound externally applied drug for treating and/or preventing male-pattern alopecia |
| ES2613888B1 (en) * | 2016-08-19 | 2017-11-16 | Enrique Blanxart Sena | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALOPECIA |
| WO2018206077A1 (en) * | 2017-05-08 | 2018-11-15 | Merz Pharma Gmbh & Co. Kgaa | Emulsion comprising finasteride |
| RS62654B1 (en) * | 2017-06-16 | 2021-12-31 | Capilli Med Gmbh | Composition to prevent hairloss and promote hairgrowth |
| MX390288B (en) * | 2018-02-06 | 2025-03-20 | Centro Int De Cosmiatria S A P I De C V | FORMULATION AND METHOD FOR THE TREATMENT OF ANDROGENIC ALOPECIA. |
| CN110448525A (en) * | 2018-05-08 | 2019-11-15 | 无锡派列博生物医药科技有限公司 | A kind of external application Finasteride lipid nanometer preparation and preparation method thereof prevented hair loss with growth-promoting hair |
| US11311529B2 (en) | 2018-11-08 | 2022-04-26 | Varsona Therapeutics, Inc. | Topical formulations of 5-α-reductase inhibitors and uses thereof |
| WO2020121329A1 (en) * | 2018-12-11 | 2020-06-18 | Dr Rathod Sudha Suresh | Minoxidil and castor oil nanoemulgel for alopecia |
| CN112773776B (en) * | 2019-11-11 | 2023-06-20 | 上海胜联医药科技有限公司 | Drug-loaded nanoparticle system |
| CN111329832B (en) * | 2020-02-08 | 2021-07-16 | 中山大学 | A kind of nano-lipid carrier microneedle for treating hair loss and its application |
| WO2021178871A1 (en) * | 2020-03-05 | 2021-09-10 | University Of Miami | Cannabidiol nanodrug formulations and methods for use the same |
| AU2020389480A1 (en) | 2020-03-30 | 2021-10-14 | Hyundaibioscience Co.,Ltd. | Ethosomal composition including ethosomes encapsulating vitamin and dexpanthenol and method for preparing the same |
| US11311556B2 (en) | 2020-05-13 | 2022-04-26 | Varsona Therapeutics, Inc. | Topical dutasteride emulsions for treating endocrine therapy-induced alopecia |
| WO2022067008A1 (en) * | 2020-09-24 | 2022-03-31 | Pro Transit Nanotherapy Llc | Compositions and methods for the treatment of hair loss and other conditions |
| CN114910567B (en) * | 2021-02-07 | 2023-11-24 | 株洲千金药业股份有限公司 | Method for detecting genotoxic impurities in finasteride and application of method |
| CN113425845B (en) * | 2021-08-10 | 2022-12-02 | 成都倍特药业股份有限公司 | Carrier preparation for preventing and/or treating alopecia and preparation method and application thereof |
| CN113797208B (en) * | 2021-11-17 | 2022-02-25 | 山东谷雨春生物科技有限公司 | Minoxidil-containing preparation and preparation method and application thereof |
| KR20230113871A (en) | 2022-01-24 | 2023-08-01 | (주) 해피론이엔지 | Construction method and structure of noise prevention between floors in buildings using foamed polyethylene mesh |
| KR102623083B1 (en) | 2022-05-02 | 2024-01-10 | (주) 해피론이엔지 | 1st mortar casting type noise prevention construction method and construction structure without resonance space |
| CN115006712B (en) * | 2022-06-28 | 2024-01-09 | 广州汇元医药科技有限公司 | Minoxidil lipid nanoparticle microneedle and preparation method and application thereof |
| CN115252549B (en) * | 2022-07-12 | 2023-09-08 | 科辉智药生物科技(无锡)有限公司 | Composition for improving efficacy of hair-growing active substance and preparation method thereof |
| CN115400085A (en) * | 2022-09-02 | 2022-11-29 | 南昌大学 | A kind of finasteride lipid vesicle and its preparation method and application |
| CN118831088B (en) * | 2023-09-06 | 2025-04-29 | 北京辰光医药科技有限公司 | Pharmaceutical preparation for treating hair loss and its preparation method and use |
| CN118831050B (en) * | 2024-09-12 | 2025-01-28 | 晨笛医药科技(上海)有限公司 | A 5α-reductase inhibitor alcohol-containing emulsion and its preparation method and application |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2659554B1 (en) * | 1990-03-16 | 1994-09-30 | Oreal | COMPOSITION FOR THE COSMETIC AND / OR PHARMACEUTICAL TREATMENT OF THE TOP LAYERS OF THE EPIDERMIS BY TOPICAL APPLICATION TO THE SKIN AND PREPARATION METHOD THEREOF. |
| US6284234B1 (en) * | 1998-08-04 | 2001-09-04 | Johnson & Johnson Consumer Companies, Inc. | Topical delivery systems for active agents |
| AU771256B2 (en) * | 1999-07-06 | 2004-03-18 | Raziel Lurie | Medicaments comprising relaxin and their use |
| KR100463167B1 (en) * | 2001-04-13 | 2004-12-23 | 주식회사 태평양 | Percutaneous Controlled Releasing Material Using Nano-sized Polymeric Particles and External Application Agent Containing the Same |
| JP4939936B2 (en) * | 2003-06-27 | 2012-05-30 | 株式會社アモーレパシフィック | Method for producing self-assembling polymer nanoparticles containing physiologically active ingredients, and external preparation composition containing the obtained self-assembling polymer nanoparticles |
| WO2005000258A1 (en) | 2003-06-27 | 2005-01-06 | Amorepacific Corporation | Self-assembled polymeric nanoparticles containing physiologically active ingredients and external application containing the nanoparticles |
| CN100539988C (en) * | 2003-06-27 | 2009-09-16 | 株式会社太平洋 | Self-aggregating polymer nanoparticles containing physiologically active ingredients and external liniment containing the same |
| US20060204588A1 (en) | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
| SG150075A1 (en) * | 2006-08-11 | 2009-03-30 | Panacea Biotec Ltd | Particles for delivery of active ingredients, process of making and compositions thereof |
| US20080175807A1 (en) | 2007-01-24 | 2008-07-24 | Fujifilm Corporation | Composition for hair |
| BRPI0700832B8 (en) * | 2007-03-16 | 2021-05-25 | Biolab Sanus Farmaceutica Ltda | topical anesthetic composition comprising suspension of polymeric nanocapsules of lidocaine and prilocaine |
| WO2009058135A1 (en) * | 2007-10-30 | 2009-05-07 | Celonova Biosciences, Inc. | Loadable polymeric microparticles for therapeutic use in alopecia and methods of preparing and using the same |
| WO2010036947A2 (en) | 2008-09-27 | 2010-04-01 | Jina Pharmaceuticals, Inc. | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
| KR20120113211A (en) * | 2009-09-11 | 2012-10-12 | 폴리카 인코포레이티드 | Intermittent Lithium Therapy and Pulsed Lithium Therapy to Regulate Hair Growth |
| ES2384060B1 (en) * | 2010-03-24 | 2013-09-23 | Lipotec S.A. | LIPID NANOPARTICLES CAPSULES. |
| BRPI1002601E2 (en) * | 2010-06-01 | 2020-06-30 | Embrapa Pesquisa Agropecuaria | nanostructured composition for veterinary use for drug administration |
-
2012
- 2012-08-31 BR BR102012022036-9A patent/BR102012022036B1/en active IP Right Grant
-
2013
- 2013-08-30 UA UAA201502698A patent/UA113774C2/en unknown
- 2013-08-30 AR ARP130103103A patent/AR092403A1/en not_active Application Discontinuation
- 2013-08-30 PE PE2015000270A patent/PE20150732A1/en not_active Application Discontinuation
- 2013-08-30 CN CN201380057183.4A patent/CN104755075B/en active Active
- 2013-08-30 MX MX2015002300A patent/MX363961B/en active IP Right Grant
- 2013-08-30 KR KR1020157008175A patent/KR102118582B1/en not_active Expired - Fee Related
- 2013-08-30 EP EP13832137.7A patent/EP2891486B1/en active Active
- 2013-08-30 US US14/424,695 patent/US9687554B2/en active Active
- 2013-08-30 MY MYPI2015700620A patent/MY174692A/en unknown
- 2013-08-30 AU AU2013308356A patent/AU2013308356B2/en active Active
- 2013-08-30 ES ES13832137.7T patent/ES2683418T3/en active Active
- 2013-08-30 JP JP2015528815A patent/JP6352265B2/en not_active Expired - Fee Related
- 2013-08-30 UY UY0001035002A patent/UY35002A/en not_active Application Discontinuation
- 2013-08-30 CA CA2883998A patent/CA2883998C/en active Active
- 2013-08-30 PE PE2019001935A patent/PE20191714A1/en unknown
- 2013-08-30 WO PCT/BR2013/000335 patent/WO2014032152A1/en active Application Filing
- 2013-08-30 DK DK13832137.7T patent/DK2891486T3/en active
- 2013-08-30 TR TR2018/10389T patent/TR201810389T4/en unknown
- 2013-08-30 IN IN1728DEN2015 patent/IN2015DN01728A/en unknown
-
2015
- 2015-02-24 ZA ZA2015/01255A patent/ZA201501255B/en unknown
- 2015-02-26 SA SA515360084A patent/SA515360084B1/en unknown
- 2015-02-27 CL CL2015000501A patent/CL2015000501A1/en unknown
- 2015-03-06 CO CO15052121A patent/CO7310520A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2883998A1 (en) | 2014-03-06 |
| UA113774C2 (en) | 2017-03-10 |
| CN104755075B (en) | 2019-07-26 |
| BR102012022036B1 (en) | 2019-10-01 |
| EP2891486A4 (en) | 2016-03-23 |
| PE20150732A1 (en) | 2015-05-17 |
| TR201810389T4 (en) | 2018-08-27 |
| AU2013308356B2 (en) | 2017-09-28 |
| JP6352265B2 (en) | 2018-07-04 |
| UY35002A (en) | 2014-03-31 |
| ES2683418T3 (en) | 2018-09-26 |
| CN104755075A (en) | 2015-07-01 |
| CA2883998C (en) | 2020-08-25 |
| US9687554B2 (en) | 2017-06-27 |
| AR092403A1 (en) | 2015-04-22 |
| KR102118582B1 (en) | 2020-06-04 |
| AU2013308356A1 (en) | 2015-04-16 |
| MX2015002300A (en) | 2016-02-10 |
| KR20150044029A (en) | 2015-04-23 |
| JP2015526484A (en) | 2015-09-10 |
| DK2891486T3 (en) | 2018-07-23 |
| MY174692A (en) | 2020-05-07 |
| CO7310520A2 (en) | 2015-06-30 |
| EP2891486B1 (en) | 2018-05-16 |
| PE20191714A1 (en) | 2019-12-05 |
| MX363961B (en) | 2019-04-09 |
| US20150216986A1 (en) | 2015-08-06 |
| ZA201501255B (en) | 2016-01-27 |
| BR102012022036A2 (en) | 2014-11-25 |
| WO2014032152A1 (en) | 2014-03-06 |
| CL2015000501A1 (en) | 2015-07-03 |
| SA515360084B1 (en) | 2016-10-03 |
| EP2891486A1 (en) | 2015-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN01728A (en) | ||
| IN2015DN01727A (en) | ||
| IN2014DN09434A (en) | ||
| MX2014015004A (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof. | |
| MX2015016983A (en) | Nuclear transport modulators and uses thereof. | |
| MX2016001788A (en) | Benzimidazolyl-methyl urea derivatives as alx receptor agonists. | |
| SG10201804817TA (en) | Delayed release compositions of linaclotide | |
| SG10201914117QA (en) | Treatment Of Myelosuppression | |
| UA115357C2 (en) | Pyridin-4-yl derivatives | |
| EP2897689A4 (en) | Systems, compositions and methods for the treatment of alopecia | |
| PH12014502465A1 (en) | Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists | |
| BR112015027436A2 (en) | Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| MX366829B (en) | Itraconazole compositions and dosage forms, and methods of using the same. | |
| EP2889287A4 (en) | Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same | |
| MX355719B (en) | Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction and xanthan gum. | |
| MX366309B (en) | Pharmaceutical composition for treating inflammation and pain. | |
| MX368640B (en) | PHARMACEUTICAL COMPOSITION FOR TREATING INFLAMMATION and PAIN. | |
| IL234087A0 (en) | Ascorbic acid derivative composition and production method of the same, ascorbic acid derivative solution, and skin external preparation | |
| IN2013CH03945A (en) |